Aquestive Therapeutics (AQST) Depreciation & Amortization (CF) (2017 - 2026)
Aquestive Therapeutics (AQST) posted quarterly Depreciation & Amortization (CF) of $113000.0 for Q1 2026, down 18.71% year-over-year from $139000.0 in Q1 2025, and down 13.08% quarter-over-quarter from $130000.0 in Q4 2025.
Aquestive Therapeutics (AQST) Depreciation & Amortization (CF) (2017 - 2026) Analysis & Trends
Aquestive Therapeutics' Depreciation & Amortization (CF) history runs 10 years deep, the most recent figure standing at $113000.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 18.71% year-over-year to $113000.0; the TTM figure through Mar 2026 stood at $522000.0 (down 19.69% YoY), while the FY2025 annual figure was $548000.0, down 23.68% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $113000.0, down from $130000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $727000.0 in Q1 2022, with the low at $113000.0 in Q1 2026.
- The 5-year median for Depreciation & Amortization (CF) is $207000.0 (2024), against an average of $300647.1.
- The sharpest annual moves came in 2023 and 2024: Depreciation & Amortization (CF) advanced 17.63% in 2023, then sank 68.52% in 2024.
- Aquestive Therapeutics' Depreciation & Amortization (CF) stood at $397000.0 in 2022, then climbed by 17.63% to $467000.0 in 2023, then sank by 68.52% to $147000.0 in 2024, then decreased by 11.56% to $130000.0 in 2025, then slipped by 13.08% to $113000.0 in 2026.
- Business Quant data shows AQST's Depreciation & Amortization (CF) at $113000.0 in Q1 2026, $130000.0 in Q4 2025, and $139000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 241.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 119.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 1.02 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 24.20 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 672.30 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 171.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Aquestive Therapeutics | 560.60 Mn | 560.60 Mn | 9.80 Mn | 136,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 136,000.00 |
| Jun 30, 2026 | 136,000.00 |
| Mar 31, 2026 | 113,000.00 |
| Mar 31, 2026 | 113,000.00 |
| Dec 31, 2025 | 130,000.00 |
| Dec 31, 2025 | 130,000.00 |
| Sep 30, 2025 | 139,000.00 |
| Sep 30, 2025 | 139,000.00 |
| Jun 30, 2025 | 140,000.00 |
| Jun 30, 2025 | 140,000.00 |
| Mar 31, 2025 | 139,000.00 |
| Mar 31, 2025 | 139,000.00 |
| Dec 31, 2024 | 147,000.00 |
| Dec 31, 2024 | 147,000.00 |
| Sep 30, 2024 | 159,000.00 |
| Sep 30, 2024 | 159,000.00 |
| Jun 30, 2024 | 205,000.00 |
| Jun 30, 2024 | 205,000.00 |
| Mar 31, 2024 | 207,000.00 |
| Mar 31, 2024 | 207,000.00 |